Patent ID: 6509360
Filing Date: 2003-01-21
Classification: C07D

Abstract:
A method of treating or inhibiting metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal in need thereof, the method comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula: wherein:B is â€”(CH2)mâ€”, â€”CH(OH)â€”, or carbonyl; R1 is hydrogen, nitro, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, or trifluoromethyl; R2 is alkyl of 1-18 carbon atoms, Het-alkyl wherein the alkyl moiety is 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, the aryl group of each being selected from phenyl, naphthyl or 1,4-benzodioxan-5-yl, each optionally substituted by from 1 to 3 groups selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, halogen, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms or dialkylamino in which each of the alkyl groups is of 1-6 carbon atoms, nitro, cyano, â€”CO2H, alkylcarbonyloxy of 2-7 carbon atoms, or alkylcarbonyl of 2-7 carbon atoms; Het is â€ƒor R2a is alkylene of 1-3 carbon atoms; G is oxygen, sulfur, or nitrogen; R3 and R4 are each, independently, hydrogen, halogen, alkyl of 1-3 carbon atoms, aryl of 6-10 carbon atoms, the aryl group of each being selected from phenyl, naphthyl or 1,4-benzodioxan-5-yl, each optionally substituted by from 1 to 3 groups selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, halogen, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms or dialkylamino in which each of the alkyl groups is of 1-6 carbon atoms, nitro, cyano, â€”CO2H, alkylcarbonyloxy of 2-7 carbon atoms, or alkylcarbonyl of 2-7 carbon atoms; R5 is hydrogen, alkyl of 1-6 carbon atoms, â€”CH(R7)R8, â€”C(CH2)nCO2R9, â€”C(CH3)2CO2R9, â€”CH(R7)(CH2)nCO2R9, or CH(R7)C6H4CO2R9; R6 is hydrogen, halogen, alkyl of 1-6 carbon atoms, or â€”OR5; m=1-6; n=1-6; R7 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, the aryl group of each being selected from phenyl, naphthyl or 1,4-benzodioxan-5-yl, each optionally substituted by from 1 to 3 groups selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, halogen, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms or dialkylamino in which each of the alkyl groups is of 1-6 carbon atoms, nitro, cyano, â€”CO2H, alkylcarbonyloxy of 2-7 carbon atoms, or alkylcarbonyl of 2-7 carbon atoms; R8 is â€”CO2R10, â€”CONHR10, tetrazole, or â€”PO3; R9 and R10 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, the aryl group of each being selected from phenyl, naphthyl or 1,4-benzodioxan-5-yl, each optionally substituted by from 1 to 3 groups selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, halogen, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms or dialkylamino in which each of the alkyl groups is of 1-6 carbon atoms, nitro, cyano, â€”CO2H, alkylcarbonyloxy of 2-7 carbon atoms, or alkylcarbonyl of 2-7 carbon atoms; or a pharmaceutically acceptable salt thereof.